RxDoctor Payments Data

Garett Rhule, MD

Internal Medicine · Williston, NDNPI 1972791259

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 34.9% of the total. 2025 is the largest year on record at $484, 2.8 times the $170 reported in 2019.

$1,097in general payments, 2019–2025

Across 42 payments — averaging $26.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$383
  • Novartis$181
  • Amgen$97
  • Pfizer$91
  • Medtronic$89
  • Lilly USA, LLC$56
  • plus $200 from 7 others

What the payments were for

  • Food & beverage$1,097100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,097 in reported general payments places this provider in the 85th percentile of 159 internal medicine providers in North Dakota.

See all internal medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$5,677
Medicare patients
45
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol35$33,656
OzempicSemaglutide24$28,194
EliquisApixaban19$18,667
TrulicityDulaglutide18$18,384
JardianceEmpagliflozin18$14,979
JanumetSitagliptin Phos/Metformin Hcl17$14,273
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,201
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,309
Albuterol Sulfate HfaAlbuterol Sulfate36$1,247
Atorvastatin Calcium118$1,031
Ventolin HfaAlbuterol Sulfate18$938
Rosuvastatin Calcium61$760
Losartan Potassium71$713
Metoprolol Succinate47$648
Olmesartan Medoxomil11$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$23$33,65635 claims
Novo NordiskOzempic$383$28,19424 claims
PfizerEliquis$91$18,66719 claims
Lilly USA, LLCTrulicity$56$18,38418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 159 internal medicine providers in North Dakota.

Other internal medicine in Williston

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →